Mutated Protein A C Domain and Its Applications

Mutations in the C domain of protein A improve alkaline stability, addressing the instability issue in protein A affinity chromatography media, enhancing purification efficiency and media durability in alkaline washing.

JP2024543701APending Publication Date: 2024-11-21BESTCHROM (SHANGHAI) BIOSCIENCES LTD +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024536181
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-17
Filing Date
2022-12-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The instability of protein A affinity chromatography media in alkaline conditions during antibody purification leads to ligand shedding, affecting adsorption capacity and service life, necessitating harsh cleaning steps that damage the media and require frequent restoration.

Method used

Mutations at specific positions (3, 6, 9, and 15) in the C domain of protein A enhance its alkaline stability, allowing for improved resistance to alkaline washing solutions without compromising binding capacity.

Benefits of technology

The mutated C domain exhibits enhanced stability in alkaline conditions, enabling more efficient and durable antibody purification processes with increased alkaline washing concentrations, thus extending the media's lifespan and maintaining binding efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543701000013
    Figure 2024543701000013
  • Figure 2024543701000014
    Figure 2024543701000014
  • Figure 2024543701000015
    Figure 2024543701000015
Patent Text Reader

Abstract

The present invention relates to a mutated Protein A C domain and its applications. Specifically, the present invention provides an isolated polypeptide, the polypeptide having a substitution mutation according to the present specification at one or more positions selected from the 3rd, 6th, 9th and 15th positions relative to the native Protein A C domain as shown in SEQ ID NO:1. The present invention further provides a fusion protein or recombinant Protein A comprising said polypeptide, as well as corresponding coding sequences, nucleic acid constructs, expression systems, isolation media, methods and uses. The isolated polypeptide according to the present invention has significantly improved alkaline stability in an alkaline wash process relative to the native C domain.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a mutated Protein A C domain and its applications. [Background technology]

[0002] In recent years, antibody drugs have attracted attention in the global pharmaceutical market due to their high specificity. Among them, monoclonal antibodies are one of the most rapidly growing fields in the biopharmaceutical industry. Monoclonal antibodies have three unique mechanisms, including targeting function, blocking function, and signal transduction function. Monoclonal antibody drugs are applied to the treatment of tumors, autoimmune diseases, infectious diseases, etc., and have been recognized to be particularly effective in the treatment of cancer.

[0003] Currently, the purification of antibody drugs is mainly achieved by capturing antibodies through the special adsorption ability of multiple domains of the affinity resin ligand Protein A to specific Fc fragments of antibodies. At present, this method is also the most mature and widely applied affinity chromatography method in terms of process technology.

[0004] However, Protein A affinity chromatography resin loses Protein A ligands during the antibody purification process. In order to prevent immune reactions to pharmaceuticals, it is necessary to remove the lost ligands in the process. Meanwhile, the rate of ligand loss is basically determined by the amino acid distribution and stability of the ligand, and the coupling method of the ligand. And, for economic reasons, chromatography media are usually used repeatedly, so a washing process is required to restore the resin to its pre-use state. Generally, washing with 0.1-0.5M standard NaOH solution (CIP) can highly efficiently remove protein precipitates, hydrophobic proteins, nucleic acids, endotoxins, viruses, etc. from the chromatography media. However, when washing with an alkaline solution, the vector is exposed to alkaline conditions, which is a very harsh atmosphere for many chromatography media containing protein affinity ligands, and the amino acids of the ligands are destroyed, which affects the adsorption capacity and service life of the media.

[0005] Therefore, how to overcome the bottleneck of Protein A affinity chromatography medium's instability in an alkaline environment and to widely apply it in the field of bioaffinity chromatography has become a current key issue. Summary of the Invention

[0006] The present invention provides mutant polypeptides of the C domain of native Protein A, which have improved alkaline stability compared to the C domain.

[0007] Specifically, the present invention provides a polypeptide having a substitution mutation at one or more positions selected from the 3rd, 6th, 9th and 15th positions relative to the native C domain of Protein A as shown in SEQ ID NO:1.

[0008] In one or more embodiments, the polypeptide has a substitution mutation at the 3rd, 6th, 9th or 15th position relative to the native C domain of protein A shown in SEQ ID NO:1. In some embodiments, the polypeptide has a substitution mutation at the 3rd and 6th, or the 3rd and 9th, or the 3rd and 15th, or the 6th and 9th, or the 6th and 15th, or the 9th and 15th positions relative to the native C domain of protein A shown in SEQ ID NO:1. In some embodiments, the polypeptide has a substitution mutation at the 3rd, 6th and 9th, or the 3rd, 6th and 15th, or the 6th, 9th and 15th positions relative to the native C domain of protein A shown in SEQ ID NO:1. In some embodiments, the polypeptide has a substitution mutation at the 3rd, 6th, 9th and 15th positions relative to the native C domain of protein A shown in SEQ ID NO:1.

[0009] In one or more embodiments, the polypeptide has a substitution mutation at position 15 and, optionally, at one or more positions selected from positions 3, 6 and 9 relative to the native C domain of Protein A as shown in SEQ ID NO:1.

[0010] In one or more embodiments, the polypeptide has substitution mutations at positions 9 and 15, and optionally substitution mutations at any one or all two positions selected from positions 3 and 6, relative to the native C domain of Protein A as shown in SEQ ID NO:1.

[0011] In one or more embodiments, the polypeptide has substitution mutations at positions 3, 9 and 15, and optionally a substitution mutation at position 6, relative to the native C domain of Protein A shown in SEQ ID NO:1.

[0012] In one or more embodiments, the substitution mutation at position 3 is N3L, N3V, or N3Y.

[0013] In one or more embodiments, the substitution mutation at position 6 is N6S, N6L, or N6E.

[0014] In one or more embodiments, the substitution mutation at position 9 is Q9I, Q9F or Q9M.

[0015] In one or more embodiments, the substitution mutation at position 15 is E15T, E15W, E15L, E15V, E15I, E15F, E15S, E15Y or E15T.

[0016] In one or more embodiments, the amino acid sequence of the polypeptide is set forth in any one of SEQ ID NOs:2-73.

[0017] In one or more embodiments, the polypeptide has an amino acid residue at position 29 that is A relative to the native C domain of Protein A as shown in SEQ ID NO:1.

[0018] A second aspect of the invention provides a polypeptide comprising: (i) a polypeptide according to any one of the embodiments of the first aspect of the invention; (ii) one or more coupling elements at the C-terminus or N-terminus of the amino acid sequence of the polypeptide according to (i); and optionally (iii) residues derived from a truncated signalling sequence.

[0019] In one or more embodiments, the coupling elements are selected from a cysteine ​​residue, a plurality of lysine residues, and a plurality of histidine residues.

[0020] A third aspect of the present invention is a fusion protein comprising 2-8 polypeptides fused together, wherein the amino acid sequence of said polypeptides comprises substitution mutations at one or more positions selected from the 3rd, 6th, 9th and 15th positions relative to the native C domain of Protein A as shown in SEQ ID NO:1.

[0021] In one or more embodiments, the polypeptide is a polypeptide according to any one of the embodiments of the first aspect of the invention.

[0022] In one or more embodiments, in the fusion protein, the 2-8 polypeptides are different from each other, partially identical, or completely identical.

[0023] In one or more embodiments, each of the polypeptides comprised in the fusion protein comprises at least an E15T, E15W, E15L, E15V, E15I, E15F, E15S, E15Y or E15T mutation, and preferably further comprises a substitution mutation at one or more of positions 3, 6 and 15 as defined herein, preferably the substitution mutation at position 3 is N3L or N3V, preferably the substitution mutation at position 6 is N3L or N3V, and preferably the substitution mutation at position 9 is Q9I or Q9F.

[0024] In one or more embodiments, in the fusion protein, the polypeptide is selected from SEQ ID NOs: 2, 3, 6, 7, 8, 9, 11-19, 21-25, 58-62, and 65-69.

[0025] In one or more embodiments, a linker sequence may or may not be present between the polypeptides.

[0026] In one or more embodiments, the linker sequence is a linker sequence that includes glycine (G) and serine (S).

[0027] In one or more embodiments, the C-terminus or N-terminus of the fusion protein further comprises one or more coupling elements.

[0028] In one or more embodiments, the coupling elements are selected from a cysteine ​​residue, a plurality of lysine residues, and a plurality of histidine residues.

[0029] In one or more embodiments, the fusion protein further comprises residues from a truncated signaling sequence.

[0030] In one or more embodiments, the amino acid sequence of the fusion protein is set forth in any one of SEQ ID NOs:75-108.

[0031] A fourth aspect of the present invention provides a recombinant Protein A, the C domain of which is a polypeptide according to any one of the embodiments of the first aspect of the present invention.

[0032] A fifth aspect of the present invention provides a nucleic acid molecule, the polynucleotide sequence of which is (1) a polynucleotide sequence encoding a polypeptide according to any one of the embodiments of the first aspect of the present invention, a polypeptide according to any one of the embodiments of the second aspect, a fusion protein according to any one of the embodiments of the third aspect, or a recombinant protein A according to any one of the embodiments of the fourth aspect; (2) A nucleic acid molecule selected from the polynucleotide sequence of (1) and a polynucleotide sequence complementary thereto.

[0033] A sixth aspect of the invention provides a nucleic acid construct, said nucleic acid construct comprising a nucleic acid molecule according to the fifth aspect of the invention.

[0034] In one or more embodiments, the nucleic acid construct is an expression cassette.

[0035] In one or more embodiments, the nucleic acid construct is an expression vector or a cloning vector.

[0036] The seventh aspect of the invention further provides an expression system comprising a nucleic acid construct or a vector according to any one of the embodiments of the sixth aspect of the invention.

[0037] In one or more embodiments, the expression system is a host cell.

[0038] An eighth aspect of the present invention provides an isolation medium comprising a polypeptide according to any one of the embodiments of the first aspect of the invention, a polypeptide according to any one of the embodiments of the second aspect, a fusion protein according to any one of the embodiments of the third aspect and / or recombinant Protein A according to any one of the embodiments of the fourth aspect coupled to a solid support.

[0039] In one or more embodiments, the polypeptide, fusion protein or recombinant Protein A is coupled to the solid support by a thioether bond.

[0040] A ninth aspect of the invention provides a chromatography column comprising an isolation medium according to the eighth aspect of the invention.

[0041] A tenth aspect of the present invention provides a method for isolating an Fc-containing protein (e.g. an immunoglobulin), said method comprising the step of contacting a sample containing the Fc-containing protein with a polypeptide according to any one of the embodiments of the first aspect of the invention, a polypeptide according to any one of the embodiments of the second aspect, a fusion protein according to any one of the embodiments of the third aspect and / or recombinant Protein A according to any one of the embodiments of the fourth aspect.

[0042] In one or more embodiments, the method comprises contacting a sample comprising an Fc-containing protein with an isolation medium according to any one of the eighth aspect of the invention or a chromatography column according to the ninth aspect of the invention. Preferably, the method further comprises, after contacting, washing the isolation medium and eluting the Fc-containing protein from the isolation medium with an elution solution.

[0043] A tenth aspect of the present invention provides the application of a polypeptide according to any one embodiment of the first aspect of the invention, a polypeptide according to any one embodiment of the second aspect, a fusion protein according to any one embodiment of the third aspect and / or recombinant Protein A according to any one embodiment of the fourth aspect of the invention in the isolation of an Fc-containing protein or in the manufacture of an isolation medium or a chromatography column for isolating an Fc-containing protein. [Brief description of the drawings]

[0044] [Figure 1A] Genetic result verification analysis diagram of SEQ ID NO: 74. 1: Plasmid, 2: Plasmid digested with XbaI-XhoI, 3: DNA Marker. [Figure 1B] FIG. 1 is a genetic result validation analysis of SEQ ID NO:75. [Figure 1C] FIG. 1 is a genetic result validation analysis of SEQ ID NO:76. [Figure 1D] FIG. 1 is a genetic result validation analysis of SEQ ID NO:77. [Figure 1E] Genetic result verification analysis diagram of SEQ ID NO: 78. 1: Plasmid, 2: Plasmid digested with XbaI-XhoI, 3: DNA Marker. [Figure 1F] Genetic result verification analysis diagram of SEQ ID NO: 79. 1: Plasmid, 2: Plasmid digested with XbaI-XhoI, 3: DNA Marker. [Figure 1G] FIG. 1 is a genetic result validation analysis of SEQ ID NO:80. [Figure 1H] Genetic result verification analysis diagram of SEQ ID NO: 84. 1: Plasmid, 2: Plasmid digested with XbaI-XhoI, 3: DNA Marker. [Figure 1I] FIG. 1 is a genetic result validation analysis of SEQ ID NO:85. [Figure 1J] FIG. 1 is a genetic result validation analysis of SEQ ID NO:86. [Figure 1K] FIG. 1 is a genetic result validation analysis of SEQ ID NO:87. [Figure 1L] Genetic result verification analysis diagram of SEQ ID NO: 101. 1: Plasmid, 2: Plasmid digested with XbaI-XhoI, 3: DNA Marker. [Figure 1M] This is a gene result verification analysis diagram of SEQ ID NO: 103. The enzyme is Ndel / HindIII, and the predicted size is 871+5k. The right diagram is the DNA marker. [Figure 1N] This is a genetic result verification analysis diagram of SEQ ID NO: 104. The enzyme is Ndel / HindIII, and the predicted size is 871+5k. The right diagram is the DNA marker. [Diagram 2] 1 is a graph showing the alkaline stability of the C domain shown in SEQ ID NO:74-90. [Diagram 3] 1 is a graph showing the alkaline stability of the C domains shown in SEQ ID NOs: 74, 92-94, and 96-107. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0045] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (e.g., in the Examples) can be combined with each other to form preferred embodiments.

[0046] As used herein, the terms "antibody" and "immunoglobulin" may be used interchangeably and have the meanings well known in the art. The antibody or immunoglobulin according to the present specification also includes an antibody fragment, and a fusion protein or complex containing an antibody fragment, as long as these fragments, fusion proteins or complexes contain the Fc portion of an antibody and can be isolated and purified by binding to Protein A. The antibody fragment may be a functionally active fragment thereof.

[0047] As used herein, amino acid residues may be described by the following abbreviations: alanine (Ala or A), arginine (Arg or R), asparaginate (Asn or N), aspartic acid (Asp or D), cysteine ​​(Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), valine (Val or V), and any amino acid residue (Xaa or X). Furthermore, herein, the amino acid sequences of peptides are conventionally written with the amino terminus (hereinafter referred to as the "N-terminus") on the left and the carboxy terminus (hereinafter referred to as the "C-terminus") on the right.

[0048] Protein A is widely used as an affinity media ligand for purifying immunoglobulins. Native protein A has five domains, namely E domain, D domain, A domain, B domain and C domain, in that order, from N-terminus to C-terminus, that bind to immunoglobulins, especially IgG. In the immunoglobulin purification process, immunoglobulins bind to protein A and are then eluted with alkali. During this process, protein A falls off the affinity chromatography media and contaminates the immunoglobulin product.

[0049] According to the present invention, it has been found that a mutant of the native C domain of Protein A (SEQ ID NO:1) obtained by performing a substitution mutation at at least one of positions 3, 6, 9 and 15 of the C domain has significantly improved alkaline stability in an alkaline washing process compared to the native C domain. The concentration of the alkaline solution used may be increased from 0.1-0.5M to 0.5-2.0M, for example, to 0.5-1.0M. This completes the present invention.

[0050] Specifically, the present invention provides a polypeptide that is a mutant of the native C domain of Protein A as set forth in SEQ ID NO:1, which has substitution mutations relative to the amino acid sequence set forth in SEQ ID NO:1 at one or more positions selected from positions 3, 6, 9 and 15 of SEQ ID NO:1, wherein the substitution mutations do not affect the existing structure of the C domain, but rather significantly improve the alkaline stability of the resulting mutant.

[0051] Preferably, in the present invention, the substitution at position 3 is a substitution of the native N with an amino acid residue selected from glycine, alanine, valine, leucine, isoleucine, tyrosine, or phenylalanine. More preferably, the substitution at position 3 is a substitution of the native N with an amino acid residue selected from leucine, valine, or tyrosine. Particularly preferably, the substitution at position 3 is a substitution of the native N with leucine or valine. In some preferred embodiments, the polypeptide of the present invention has a substitution mutation at position 3 relative to SEQ ID NO:1. Preferably, the amino acid sequence of the polypeptide is set forth in SEQ ID NO:2, 3, or 4.

[0052] Preferably, in the present invention, the substitution mutation at position 6 is preferably a substitution of the native N with glycine, alanine, serine, threonine, leucine, isoleucine, valine, glutamic acid or aspartic acid. More preferably, the substitution at position 6 is a substitution of the native N with an amino acid residue selected from serine, leucine or glutamic acid. Particularly preferably, the substitution at position 6 is a substitution of the native N with leucine or glutamic acid. In some preferred embodiments, the polypeptide of the present invention has a substitution mutation at position 6 relative to SEQ ID NO:1. Preferably, the amino acid sequence of the polypeptide is as shown in SEQ ID NO:5, 6 or 7.

[0053] Preferably, in the present invention, the substitution mutation at position 9 is a substitution of the natural Q with glycine, alanine, leucine, valine, tyrosine, serine, isoleucine, arginine, phenylalanine or methionine, more preferably with isoleucine, phenylalanine or methionine. In some preferred embodiments, the polypeptide of the present invention has a substitution mutation at position 9 relative to SEQ ID NO:1. Preferably, the amino acid sequence of the polypeptide is as shown in SEQ ID NO:8, 9 or 10.

[0054] Preferably, in the present invention, the substitution mutation at position 15 is a substitution of the native E with glycine, leucine, alanine, methionine, phenylalanine, tyrosine, isoleucine, serine, threonine, tryptophan, valine, aspartic acid, glutamic acid or arginine. More preferably, the substitution at position 15 is a substitution of the native E with threonine, tryptophan, leucine, valine, isoleucine, phenylalanine, serine, tyrosine or aspartic acid residue. In some preferred embodiments, the polypeptide of the present invention has a substitution mutation at position 15 relative to SEQ ID NO:1. Preferably, the amino acid sequence of the polypeptide is set forth in any one of SEQ ID NOs:11-19.

[0055] In a preferred embodiment, the polypeptide of the invention has substitution mutations at any two positions selected from positions 3, 6, 9 and 15, three positions or all four positions relative to the native C domain of Protein A as shown in SEQ ID NO:1. Preferably, said substitution mutations are as set out above. More preferably, said substitution mutation at position 9 is Q9I, Q9F or Q9M, said substitution mutation at position 3 is N3L, N3V or N3Y, said substitution mutation at position 6 is N6S, N6L or N6E and said substitution mutation at position 15 is E15T, E15W, E15L, E15V, E15I, E15F, E15S, E15Y or E15T.

[0056] In some embodiments, the polypeptide of the present invention comprises the amino acid sequence shown in SEQ ID NO: 109, i.e., ADX1KFX2KEX3QNAFYX4ILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK, in which X1 is selected from glycine, alanine, valine, leucine, isoleucine, tyrosine, or phenylalanine, and preferably selected from leucine, valine, or tyrosine. X2 is selected from glycine, alanine, serine, threonine, leucine, isoleucine, valine, glutamic acid, or aspartic acid, and preferably selected from serine, leucine, or glutamic acid. X3 is selected from glycine, alanine, leucine, valine, tyrosine, serine, isoleucine, arginine, phenylalanine, or methionine, and preferably selected from isoleucine, phenylalanine, or methionine. X4 is selected from glycine, leucine, alanine, methionine, phenylalanine, tyrosine, isoleucine, serine, threonine, tryptophan, valine, aspartic acid, glutamic acid, and arginine, and is preferably selected from threonine, tryptophan, leucine, valine, isoleucine, phenylalanine, serine, tyrosine, and aspartic acid.

[0057] More preferably, the polypeptide of the present invention has a substitution mutation at position 3 and optionally at one position selected from positions 6, 9 and 15 relative to the native C domain of Protein A as shown in SEQ ID NO:1. Preferably, said substitution mutation is as shown in any one of the above embodiments. More preferably, said substitution mutation at position 3 is N3L, N3V or N3Y. When said substitution mutation at position 6 is present, said substitution mutation is N6S, N6L or N6E, preferably N6L or N6E. When said substitution mutation at position 9 is present, said substitution mutation is Q9I or Q9F. When said substitution mutation at position 15 is present, said substitution mutation is E15W, E15L, E15V, E15I or E15F.

[0058] More preferably, the polypeptide of the invention has a substitution mutation at position 6 and optionally at one position selected from positions 3, 6 and 15 relative to the native C domain of Protein A as shown in SEQ ID NO:1. Preferably, said substitution mutation is as shown in any one of the above embodiments. More preferably, said substitution mutation at position 6 is N6S, N6L or N6E, preferably N6L or N6E. When having a substitution mutation at position 3, the substitution mutation is N3L, N3V or N3Y. When having a substitution mutation at position 9, the substitution mutation is Q9I or Q9F. When having a substitution mutation at position 15, the substitution mutation is E15W, E15L, E15V, E15I or E15F.

[0059] More preferably, the polypeptide of the invention has a substitution mutation at position 9 and optionally at one position selected from positions 3, 6 and 15 relative to the native C domain of Protein A as shown in SEQ ID NO:1. Preferably, said substitution mutations are as described above. More preferably, said substitution mutation at position 9 is Q9I or Q9F, said substitution mutation at position 3 is N3L, N3V or N3Y, said substitution mutation at position 6 is N6S, N6L or N6E and said substitution mutation at position 15 is E15T, E15W, E15L, E15V, E15I, E15F, E15S, E15Y or E15T. More preferably, said substitution mutation at position 9 is Q9I or Q9F. When said substitution mutation at position 3 is present, the substitution mutation is N3L, N3V or N3Y. When it has a substitution mutation at position 6, the substitution mutation is N6S, N6L or N6E, preferably N6L or N6E. When it has a substitution mutation at position 15, the substitution mutation is E15W, E15L, E15V, E15I or E15F.

[0060] More preferably, the polypeptide of the invention has a substitution mutation at position 15 and optionally at one of positions 3, 6 and 9 relative to the native C domain of protein A shown in SEQ ID NO:1. Preferably, said substitution mutation is as described above. More preferably, the substitution mutation at position 15 is E15T, E15W, E15L, E15V, E15I, E15F, E15S, E15Y or E15T, said substitution mutation at position 9 is Q9I, Q9F or Q9M, the substitution mutation at position 3 is N3L, N3V or N3Y and the substitution mutation at position 6 is N6S, N6L or N6E. More preferably, the polypeptide of the invention has a substitution mutation at position 15 and optionally at one of positions 3, 6 and 9 relative to the native C domain of protein A shown in SEQ ID NO:1. Preferably, the exemplary amino acid sequences of the polypeptides are shown in SEQ ID NOs:20-37. More preferably, relative to the native C domain of Protein A shown in SEQ ID NO:1, the polypeptides of the invention have a substitution mutation at position 15 and at any two positions selected from positions 3, 6 and 9. Preferably, the exemplary amino acid sequences of the polypeptides are shown in SEQ ID NOs:38-57. More preferably, relative to the native C domain of Protein A shown in SEQ ID NO:1, the polypeptides of the invention have a substitution mutation at position 15 and at positions 3, 6 and 9. Preferably, the exemplary amino acid sequences of the polypeptides are shown in SEQ ID NOs:58-73.

[0061] In some preferred embodiments, the polypeptides of the invention have substitution mutations at positions 9 and 15, and optionally at any one or all two positions selected from positions 3 and 6, relative to the native C domain of Protein A shown in SEQ ID NO:1. In more preferred embodiments, the polypeptides have substitution mutations at positions 3, 9 and 15, and optionally at position 6, relative to the native C domain of Protein A shown in SEQ ID NO:1. Preferably, the substitution mutations are as set forth above. More preferably, the substitution mutation at position 9 is Q9I, Q9F or Q9M, the substitution mutation at position 3 is N3L, N3V or N3Y, the substitution mutation at position 6 is N6S, N6L or N6E, and the substitution mutation at position 15 is E15T, E15W, E15L, E15V, E15I, E15F, E15S, E15Y or E15T.

[0062] In some preferred embodiments, the polypeptides of the invention have substitution mutations at positions 3, 6, 9 and 15 relative to the native C domain of Protein A shown in SEQ ID NO:1. Among these, the substitution mutation at position 3 is N3L or N3V, the substitution mutation at position 6 is N6L or N6E, the substitution mutation at position 9 is Q9I or Q9F, and the substitution mutation at position 15 is N6L or N6E. 5 The substitution mutation at is E15W, E15V, E15I or E15L.

[0063] As is known in the art, the alkaline resistance of the resulting mutant can be improved by mutating the 29th amino acid residue G in the native C domain of Protein A to A. Therefore, in a preferred embodiment of the present invention, in addition to the mutations at one or more of positions 3, 6, 9 and 15, the polypeptide of the present invention may further have a G29A mutation at position 29.

[0064] The polypeptide of the present invention can be used as it is as a ligand for binding and isolating immunoglobulins. Therefore, in some embodiments, the polypeptide further comprises one or more coupling elements for coupling the polypeptide to a solid support at its C-terminus or N-terminus. Suitable coupling elements are well known in the art and include, but are not limited to, a cysteine ​​residue, a plurality of lysine residues (e.g., 3-15 or 5-10), and a plurality of histidine residues (e.g., 3-15 or 5-10). The coupling element may be a cysteine ​​residue and located at the C-terminus of the polypeptide, and the thiol group of the cysteine ​​residue reacts with an electrophilic group on the solid support to couple the polypeptide to the solid support. The coupling element may be directly linked to the polypeptide, or may be linked to the N- or C-terminus of the polypeptide via a linker. The linker may be one commonly used in the art, and its presence does not affect the binding activity of the polypeptide. An exemplary linker is a linker sequence that includes or consists of G and S, and is typically 2-20 amino acid residues in length. An exemplary linker sequence is (GS) n , (G.S.S.) n and (GSSS) n where n is an integer from 2 to 10, but the total length of the linker is typically 20 amino acid residues or less. The polypeptide may further comprise a number of amino acid residues (e.g., 15 or less, 10 or less, or 5 or less) at the N-terminus that are derived from the cloning process or from a signaling sequence. As a specific example, the polypeptide may comprise AQ at the N-terminus.

[0065] The present invention further provides a fusion protein, which is formed by fusing 2-8 polypeptides according to the present invention. Each of the polypeptides forming the fusion protein may be completely different, partially identical, or completely identical. The polypeptides may be directly linked to each other via peptide bonds at the C-terminus and N-terminus, respectively, or any two polypeptides may be linked by a linker. The linker may be one commonly used in the art, and its presence does not affect the binding activity of the polypeptide. An exemplary linker is a linker sequence containing or consisting of G and S, and is usually 2-20 amino acid residues in length. An exemplary linker sequence is (GS) n , (G.S.S.) n and (GSSS) n where n is an integer from 2 to 10, but the total length of the linker is usually 20 amino acid residues or less.

[0066] The fusion protein can be used as a ligand to bind and isolate immunoglobulins. Therefore, in some embodiments, the fusion protein further comprises one or more coupling elements for coupling the fusion protein to a solid support at its C-terminus or N-terminus. Suitable coupling elements are well known in the art and include, but are not limited to, a cysteine ​​residue, multiple lysine residues (e.g., 3-15 or 5-10), and multiple histidine residues (e.g., 3-15 or 5-10). The coupling element may be a cysteine ​​residue and located at the C-terminus of the fusion protein, and the thiol group in the cysteine ​​residue reacts with an electrophilic group in the solid support to couple the fusion protein to the solid support. The coupling element may be directly linked to the polypeptide, or may be linked to the N- or C-terminus of the polypeptide via a linker. The linker may be one commonly used in the art, and its presence does not affect the binding activity of the polypeptide. An exemplary linker is a linker sequence that includes or consists of G and S, and is typically 2-20 amino acid residues in length. An exemplary linker sequence is (GS)n , (G.S.S.) n and (GSSS) n where n is an integer from 2 to 10, but the total length of the linker is typically 20 amino acid residues or less. The fusion protein may further comprise a number of amino acid residues (e.g., 15 or less, 10 or less, or 5 or less) at the N-terminus that are derived from the cloning process or from a signaling sequence. As a specific example, the fusion protein may comprise AQ at its N-terminus. The amino acid sequences of exemplary fusion proteins are set forth in any one of SEQ ID NOs:75-108.

[0067] The present invention further provides a recombinant protein A, the C domain of which is a polypeptide according to any embodiment of the present invention. The other domains of the recombinant protein A may be E, D, A and B domains (or Z domain, i.e., modified domains of B domain) well known in the art, including natural E, D, A and B domains, as well as known E, D, A and / or B domains (e.g., Z domains) that have been mutated but still retain biological activity. In addition to using the polypeptide of the present invention as the C domain, mutations or modifications made to other parts of protein A known in the art can be used as the recombinant protein A of the present invention.

[0068] The present specification also includes a polypeptide, a fusion protein, and a recombinant protein A having at least 85% sequence identity with a polypeptide, a fusion protein, or a recombinant protein A according to any one of the embodiments of the present specification, and a substitution mutation according to any one of the embodiments of the present specification at an amino acid position selected corresponding to one or more of 3, 6, 9, and 15 of SEQ ID NO:1. Preferably, the amino acid residue corresponding to the 29th amino acid residue of the native C domain of protein A in these polypeptides, as well as in the fusion protein and the recombinant protein A, is A. In the present specification, "at least 85% identity" with respect to amino acid sequences and nucleotide sequences means 85% or more identity, preferably 90% or more identity, more preferably 95% or more identity, more preferably 97% or more identity, more preferably 98% or more identity, and even more preferably 99% or more identity. The identity of two sequences can be calculated and aligned by tools well known in the art, including BLASTP, which is used for aligning amino acid sequences. In a preferred embodiment, the present invention includes variants of the amino acid sequences set forth in any one of SEQ ID NOs:2-73 and 75-108, each of which has at least 85%, preferably at least 90%, more preferably at least 97%, more preferably at least 99% sequence identity with the corresponding parent sequence, and wherein the amino acid residues at positions 3, 6, 9 and 15 of the corresponding parent remain the amino acid residues of the corresponding parent.

[0069] The present invention also includes nucleic acid molecules encoding the above-mentioned polypeptides, fusion proteins and recombinant Protein A, as well as complementary sequences thereof. The present invention includes all forms of the nucleic acid molecules of the present invention, including RNA and DNA. A complementary sequence in accordance with the present invention should be understood as a complementary sequence that is approximately the same length as the nucleic acid molecule.

[0070] The present invention also includes a nucleic acid construct comprising the nucleic acid molecule or a complementary sequence thereof. The nucleic acid construct may be an expression cassette comprising a promoter, the nucleic acid molecule, and a transcription termination sequence. Promoters and transcription termination sequences are well known in the art, and a person skilled in the art can appropriately select the promoter and transcription termination sequence depending on the host cell for expressing the polypeptide, fusion protein, or recombinant protein A.

[0071] In some embodiments, the nucleic acid construct is a vector, including expression vectors and cloning vectors. Expression vectors are vectors suitable for expressing foreign genes, such as nucleic acid molecules encoding the polypeptides, fusion proteins, or recombinant protein A of the present invention, in host cells, and include prokaryotic and eukaryotic expression vectors. Eukaryotic expression systems include yeast expression systems, mammalian cell expression systems, and insect cell expression systems. Cloning vectors are for amplifying target genes (e.g., nucleic acid molecules encoding the polypeptides, fusion proteins, or recombinant protein A of the present invention) in host cells. Cloning vectors include plasmid vectors, phage vectors, viral vectors, and any combination thereof, or vectors in combination with other genomic DNA. The most common host cell for molecular cloning is E. coli.

[0072] The present invention further provides an expression system comprising the nucleic acid molecule, nucleic acid construct or vector disclosed herein. The expression system is, for example, a Gram-positive or Gram-negative prokaryotic host cell system, such as E. coli or Bacillus, modified to express the polypeptide, fusion protein or recombinant Protein A of the present invention. In some embodiments, the expression system is a eukaryotic host cell system of yeast, such as Pichia or Saccharomyces.

[0073] The present invention further provides an isolation medium for isolating immunoglobulins or Fc-containing proteins. The isolation medium of the present invention comprises a polypeptide, a fusion protein and / or recombinant Protein A according to any one of the embodiments of the present invention coupled to a solid support. Due to the improved alkaline stability of the polypeptide, the fusion protein and the recombinant Protein A of the present invention, the isolation medium of the present invention can withstand strong alkaline conditions (0.5-2.0 M NaOH) during washing.

[0074] The solid phase support (matrix) in the isolation medium of the present invention is any solid phase support (matrix) known in the art and used for the isolation of immunoglobulins or Fc-containing proteins.

[0075] In the present specification, the shape of the solid support may be any shape, such as particles, membranes, plates, tubes, needles, fibers, etc. The solid support of the present invention may be a porous or non-porous material. In some embodiments, the solid support is a bead or particle type, porous or non-porous. The bead or particle type matrix may be used as a packed bed or in a suspension type, which includes an expanded bed, but the particles or beads are free to move.

[0076] When the solid support is a particle, the preferred particle size is 20-200 μm. For example, when the solid support is a synthetic polymer, the preferred particle size is 20-100 μm, preferably 30-80 μm. When the solid support is a polysaccharide, the preferred particle size is 50-200 μm, more preferably 60-150 μm. In the present specification, the "particle size" is the volume average diameter measured by the laser diffraction method of ISO 13320 and JIS Z 8825-1.

[0077] Examples of solid supports include, but are not limited to, polyhydroxy-containing polymers such as polysaccharides, including dextran, starch, cellulose, pullulan, agar, agarose, etc. In a preferred embodiment, the solid support comprises agar or agarose.

[0078] In some embodiments, the solid support of the present invention is a synthetic polymer having a hydrophilic surface. For example, these polymers may be polymers having hydroxyl groups, carboxyl groups, aminocarbonyl groups, amino groups, or oligoethyleneoxy groups or polyethyleneoxy groups on the outer surface (and also on the inner surface, if present) by hydrophilization treatment, and are preferably synthetic polymers of copolymers formed by crosslinking polyfunctional monomers such as polyfunctional (meth)acrylates and divinylbenzene. Exemplary synthetic polymers include polyvinyl alcohol, polystyrene, polystyrene divinylbenzene, polyhydroxyalkyl acrylates, polyhydroxyalkyl methacrylates, polyacrylamides, and polymethacrylamides. When the polymer surface is hydrophobic, the surface may be hydrophilized so that the hydrophilic groups are exposed to the surrounding aqueous liquid.

[0079] In some embodiments, solid supports of the present invention include supports that are inorganic in nature, including, but not limited to, silica and zirconia.

[0080] In some embodiments, a solid support of the invention is in the form of a surface, chip, capillary, or filter, such as a membrane.

[0081] In the present invention, the polypeptide, fusion protein and recombinant protein A of the present invention are coupled to the corresponding solid support by conventional coupling techniques through the thiol, amino and / or carboxyl groups contained therein. Conventional coupling reagents include, but are not limited to, bicyclic oxides, epichlorohydrin, CNBr and N-hydroxysuccinimide. The introduction of a spacer group between the solid support and the polypeptide, fusion protein and recombinant protein A of the present invention can facilitate chemical coupling between them and the solid support.

[0082] In some embodiments, the polypeptide, fusion protein, or recombinant protein A of the present invention is coupled to a solid support via a thioether bond. In some embodiments, the polypeptide, fusion protein, or recombinant protein A of the present invention is coupled via a cysteine ​​at its C-terminus. In particular, the thiol group of the cysteine ​​is effectively coupled to electrophilic groups, such as epoxy groups, halohydrin groups, on the solid support to form a thioether bridge coupling.

[0083] In the isolation medium of the invention, the concentration of the ligand (e.g. the polypeptide, fusion protein and / or recombinant Protein A according to the invention) coupled to the solid support is usually 5-20 mg / ml, e.g. 5-15 mg / ml. The amount of said bound ligand coupled is controlled by adjusting the concentration of the polypeptide, fusion protein and / or recombinant Protein A used in the coupling process, the coupling conditions used and / or the pore structure of the solid support used.

[0084] The invention further provides a chromatography column comprising the isolation medium of the invention. Typically, the isolation medium of the invention is packed into a chromatography column.

[0085] The present invention further provides a method for isolating an Fc-containing protein (e.g., an immunoglobulin), the method comprising contacting a sample containing the Fc-containing protein with a polypeptide, fusion protein and / or recombinant Protein A according to any one of the embodiments herein. In some embodiments, the method comprises contacting the sample with an isolation medium or a chromatography column according to any one of the embodiments herein.

[0086] Specifically, in some embodiments, the method comprises: (1) contacting a sample containing an Fc-containing protein with an isolation medium according to any one of the embodiments herein; (2) washing the isolation medium; and (3) eluting the Fc-containing protein from the isolation medium; and (4) washing the isolation medium.

[0087] In the present specification, the sample may be an Fc-containing protein, in particular an immunoglobulin. Preferably, the immunoglobulin in the present specification is an IgG.

[0088] The detergent for washing the isolation medium, the elution solution for eluting the protein, and the washing solution for washing the isolation medium used in the method are the usual detergent, elution solution, and washing solution in the field (particularly in the field of protein A chromatography). For example, the detergent may be a PBS buffer. The elution solution may be a solution or buffer with a pH≦5, preferably the pH of the elution solution is 2.5-5 or 3-5. In some embodiments, the pH of the elution solution is 11 or higher, for example, the pH of the elution solution is 11-14 or 11-13. In some embodiments, elution is performed with a citrate solution, for example, a sodium citrate solution. The washing solution is usually alkaline and may have a pH of 13-14. In some embodiments, the washing solution is a sodium hydroxide solution or a potassium hydroxide solution, and the concentration is 0.1-2.0M, for example, 0.5-2.0M or 0.5-1.0M.

[0089] In some embodiments, the methods herein further comprise the step of collecting the eluate and isolating and purifying the protein, which may be further isolated and purified by anion or cation exchange chromatography, hybrid ion exchange chromatography, and / or hydrophobic interaction chromatography, depending on the isolated protein.

[0090] The present invention further provides the application of the polypeptide, fusion protein and Protein A according to any one of the embodiments herein in the isolation and purification of Fc-containing proteins, or in the manufacture of an isolation medium for isolating and purifying Fc-containing proteins.

[0091] The sequences relevant to this specification are as follows: SEQ ID NO:1 (native C domain) ADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0092] SEQ ID NO:2(N3L) ADLKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0093] SEQ ID NO:3(N3V) ADVKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0094] SEQ ID NO:4(N3Y) ADYKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0095] SEQ ID NO:5(N6S) ADNKFSKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0096] SEQ ID NO:6(N6L) ADNKFLKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0097] SEQ ID NO:7(N6E) ADNKFEKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0098] SEQ ID NO:8(Q9I) ADNKFNKEIQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0099] SEQ ID NO:9(Q9F) ADNKFNKEFQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0100] SEQ ID NO:10(Q9M) ADNKFNKEMQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0101] SEQ ID NO:11(E15T) ADNKFNKEQQNAFYTILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0102] SEQ ID NO:12(E15W) ADNKFNKEQQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0103] SEQ ID NO:13(E15L) ADNKFNKEQQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0104] SEQ ID NO:14(E15V) ADNKFNKEQQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0105] SEQ ID NO:15(E15I) ADNKFNKEQQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0106] <h2 style=";text-align:left;direction:ltr">SEQ ID NO:16(E15F)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEQQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0107] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:17(E15S)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEQQNAFYSILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0108] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:18(E15Y)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEQQNAFYYILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0109] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:19(E15D)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEQQNAFYDILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0110] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:20(Q9I,E15T)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYTILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0111] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:21(Q9I,E15W)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0112] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:22(Q9I,E15L)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0113] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:23(Q9I,E15V)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0114] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:24(Q9I,E15I)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0115] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:25(Q9I,E15F)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0116] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:26(Q9I,E15S)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYSILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0117] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:27(Q9I,E15Y)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYYILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0118] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:28(Q9I,E15D)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEIQNAFYDILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0119] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:29(Q9F,E15T)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEFQNAFYTILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0120] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:30(Q9F,E15W)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADNKFNKEFQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0121] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:31(Q9F,E15L)<h2 style=";text-align:left;direction:ltr"> ADNKFNKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0122] SEQ ID NO:32(Q9F,E15V) ADNKFNKEFQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0123] SEQ ID NO:33(Q9F,E15I) ADNKFNKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0124] SEQ ID NO:34(Q9F,E15F) ADNKFNKEFQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0125] SEQ ID NO:35(Q9F,E15S) ADNKFNKEFQNAFYSILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0126] SEQ ID NO:36(Q9F,E15Y) ADNKFNKEFQNAFYYILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0127] SEQ ID NO:37(Q9F,E15D) ADNKFNKEFQNAFYDILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0128] SEQ ID NO:38(N3L,Q9I,E15W) ADLKFNKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK <h2 style=";text-align:left;direction:ltr">

[0129] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:39(N3L,Q9I,E15L)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADLKFNKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0130] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:40(N3L,Q9I,E15V)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADLKFNKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0131] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:41(N3L,Q9I,E15I)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADLKFNKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0132] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:42(N3L,Q9I,E15F)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADLKFNKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0133] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:43(N3V,Q9I,E15W)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADVKFNKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0134] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:44(N3V,Q9I,E15L)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADVKFNKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0135] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:45(N3V,Q9I,E15V)<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADVKFNKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0136] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:46(N3V,Q9I,E15I) ADVKFNKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0137] SEQ ID NO:47(N3V,Q9I,E15F) ADVKFNKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0138] SEQ ID NO:48(N6L,Q9F,E15W) ADNKFLKEFQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0139] SEQ ID NO:49(N6L,Q9F,E15L) ADNKFLKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0140] SEQ ID NO:50(N6L,Q9F,E15V) ADNKFLKEFQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0141] SEQ ID NO:51(N6L, Q9F,E15I) ADNKFLKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0142] SEQ ID NO:52(N6L,Q9F,E15F) ADNKFLKEFQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0143] SEQ ID NO:53(N6E,Q9F,E15W) ADNKFEKEFQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0144] SEQ ID NO:54(N6E,Q9F,E15L) ADNKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0145] SEQ ID NO:55(N6E,Q9F,E15V) ADNKFEKEFQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0146] SEQ ID NO:56(N6E, Q9F,E15I) ADNKFEKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0147] SEQ ID NO:57(N6E,Q9F,E15F) ADNKFEKEFQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0148] SEQ ID NO:58(N3L,N6L,Q9I,E15W) ADLKFLKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0149] SEQ ID NO:59(N3L,N6L,Q9I,E15L) ADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0150] SEQ ID NO:60(N3Y,N6E,Q9I,E15L) ADYKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0151] SEQ ID NO:61(N3Y,N6E,Q9I,E15I) ADYKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0152] SEQ ID NO:62(N3V,N6L,Q9I,E15V) ADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0153] SEQ ID NO:63(N3V,N6E,Q9I,E15L) ADVKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0154] SEQ ID NO:64(N3V,N6E,Q9I,E15I) ADVKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0155] SEQ ID NO:65(N3V,N6E,Q9I,E15F) ADVKFEKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0156] SEQ ID NO:66(N3L,N6L,Q9F,E15W) ADLKFLKEFQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0157] SEQ ID NO:67(N3L,N6L,Q9F,E15I) ADLKFLKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0158] SEQ ID NO:68(N3L,N6E,Q9F,E15L) ADLKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0159] SEQ ID NO:69(N3V,N6L,Q9F,E15V) ADVKFLKEFQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0160] SEQ ID NO:70(N3V,N6E,Q9F,E15I) ADVKFEKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0161] SEQ ID NO:71(N3V,N6E,Q9F,E15F) ADVKFEKEFQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0162] SEQ ID NO:72(N3L,N6E,Q9F,E15I) ADLKFEKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0163] SEQ ID NO:73(N3V,N6L,Q9F,E15L) ADVKFLKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0164] SEQ ID NO:74 (native C domain)4 ADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0165] SEQ ID NO:75(N3L)4 ADLKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0166] SEQ ID NO:76(N3V)4 ADVKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFNKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0167] SEQ ID NO:77(N6L)4 ADNKFLKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFLKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFLKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFLKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0168] SEQ ID NO:78(N6E)4 ADNKFEKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFEKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFEKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFEKEQQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0169] SEQ ID NO:79(Q9I)4 ADNKFNKEIQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0170] SEQ ID NO:80(Q9F)4 ADNKFNKEFQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEFQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEFQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEFQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0171] SEQ ID NO:81(Q9M)4 ADNKFNKEMQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEMQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEMQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEMQNAFYEILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0172] SEQ ID NO:82(E15T)4 ADNKFNKEQQNAFYTILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYTILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYTILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYTILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0173] SEQ ID NO:83(E15W)4 ADNKFNKEQQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0174] SEQ ID NO:84(E15L)4 ADNKFNKEQQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0175] SEQ ID NO:85(E15V)4 ADNKFNKEQQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0176] SEQ ID NO:86(E15I)4 ADNKFNKEQQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0177] SEQ ID NO:87(E15F)4 ADNKFNKEQQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0178] SEQ ID NO:88(E15S)4 ADNKFNKEQQNAFYSILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYSILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYSILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYSILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0179] SEQ ID NO:89(E15Y)4 ADNKFNKEQQNAFYYILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYYILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYYILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYYILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0180] SEQ ID NO:90(E15D)4 ADNKFNKEQQNAFYDILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYDILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYDILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEQQNAFYDILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0181] SEQ ID NO:91(Q9I,E15W)4 ADNKFNKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0182] SEQ ID NO:92(Q9I,E15L)4 ADNKFNKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0183] SEQ ID NO:93(Q9I,E15V)4 ADNKFNKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0184] SEQ ID NO:94(Q9I,E15I)4 ADNKFNKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0185] SEQ ID NO:95(Q9I,E15F)4 ADNKFNKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADNKFNKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0186] SEQ ID NO:96(N3L,N6L,Q9I,E15W)4 ADLKFLKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYWILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0187] SEQ ID NO:97(N3L,N6L,Q9I,E15L)4 ADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0188] SEQ ID NO:98(N3Y,N6E,Q9I,E15I)4 ADYKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADYKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADYKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADYKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0189] SEQ ID NO:99(N3V,N6L,Q9I,E15V)4 ADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0190] SEQ ID NO:100(N3V,N6E,Q9I,E15F)4 ADVKFEKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYFILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0191] SEQ ID NO:101(N3Y,N6E,Q9I,E15L)4 ADYKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADYKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADYKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADYKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0192] SEQ ID NO:102(N3L,N6L,Q9F,E15I)4 ADLKFLKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEFQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0193] SEQ ID NO:103(N3V,N6E,Q9I,E15L)4 ADVKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0194] SEQ ID NO:104(N3V,N6E,Q9I,E15I)4 ADVKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0195] SEQ ID NO:105(N3L,N6L,Q9I,E15L)6 ADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFLKEIQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0196] SEQ ID NO:106(N3L,N6E,Q9I,E15I)6 ADLKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEIQNAFYIILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0197] SEQ ID NO:107(N3V,N6L,Q9I,E15V)6 ADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADVKFLKEIQNAFYVILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK

[0198] SEQ ID NO:108(N3L,N6E,Q9F,E15L)6 ADLKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK ADLKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPKADLKFEKEFQNAFYLILHLPNLTEEQRNGFIQSLKDDPSVSKEILAEAKKLNDAQAPK EXAMPLES

[0199] The present invention will be described below with specific examples. These examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The methods and materials used in the examples are conventional methods and materials in the art unless otherwise specified, and some reagents are commercially available.

[0200] Manufacturing Example 1. Optimization of C domain mutants We commissioned the gene synthesis to Biological Engineering (Shanghai) Co., Ltd. The specific steps are as follows: Based on the designed sequence, the required primers were constructed. PCR reaction was carried out using pfu high temperature polymerase. The amount of each component used in PCR was: primer concentration was 10 D, dissolved in 400 μl ddH2O. TIFF2024543701000001.tif431301st PCR process: TIFF2024543701000002.tif2859

[0201] The first PCR product is used as a template for the second amplification: TIFF2024543701000003.tif35120

[0202] Second PCR process: TIFF2024543701000004.tif3162

[0203] The PCR amplified products are subjected to 1% agarose-1X TAE electrophoresis.

[0204] The PCR product P2 is collected and purified using B610353-1000 (EZ-10 column-type DNA gel collection reagent kit) manufactured by Seibutsu Kogyo Co., Ltd., and prepared for use.

[0205] Clone construction Vector Linearization Digest: TIFF2024543701000005.tif30121The above system was placed in a 37°C thermostatic water bath and reacted for 1 hour.

[0206] TIFF2024543701000006.tif29120The above system was placed in a 37°C thermostatic water bath and reacted for 2 hours.

[0207] The double digested product is subjected to 1% agarose-1X TAE electrophoresis, and the digested product P2 and vector V (pET28a+) are recovered and purified using B610353-1000 (EZ-10 column-type DNA gel recovery reagent kit) manufactured by Seibutsu Kogyo Co., Ltd., and prepared for use.

[0208] The recovered and purified target DNA fragment P2 and vector V are ligated using the T4 DNA ligase system. TIFF2024543701000007.tif31137The above ligation mixture is left at 16°C for 1 hour. The above ligation solution was transferred to BL21(DE3) competence, and positive clones were detected, selected, and sequenced.

[0209] 2. Expression and purification of C domain mutants A single recombinant plasmid is transformed into E. coli, and then fermented and cultured in LB liquid medium for inducible expression. After fermentation, the cells are harvested, the cell walls are destroyed by pyrolysis to release the expression product, and then centrifuged. The isolated liquid is purified by IgG affinity medium, the isolated liquid is sample-loaded through the affinity medium, the medium is washed with 10 mM phosphate buffer, the target protein is collected in pH 3.8 buffer, adjusted to neutral, and stored for use.

[0210] 3. Preparation of affinity chromatography media using C domain mutants The obtained C domain mutants were used to prepare affinity chromatography media by conventional methods. An exemplary preparation process specifically includes the following steps: a. Activation 10 g of high-rigidity agarose was taken, washed with purified water, and dried by suction. 10 g of the above agarose was weighed, and 20 mL of purified water was added. 0.2 g of sodium hydroxide and 10 mL of epoxychloropropane were added to a 100 mL flask, and the mixture was reacted at a constant temperature of 27°C for 2 hours. The activated gel was washed with 1 L of water to obtain activated agarose microspheres. b. Crosslinking The activated agarose microspheres were placed in a 100 mL flask, and 150 mg NaHCO3, 10 mg Na2CO3, 150 mg NaCl, and 10 mg EDTA were added. After uniform stirring, 50 mL of recombinant Protein A solution was added and reacted at a constant temperature of 34°C for 8 hours to complete the cross-linking. c. Blocking The crosslinked product was added to 100 mL of blocking buffer (ethanolamine solution), the pH was adjusted to 8.6 with sodium hydroxide, and the reaction was carried out at a constant temperature of 26°C for 2 hours to complete the blocking of the remaining epoxy groups and reduce their effects.

[0211] The C domain mutants of the present invention were prepared by the above method. The analysis results of the C domain mutants shown in exemplary SEQ ID NOs: 74-80, 84-87, 101, 103 and 104 are shown in Figures 1A to 1N.

[0212] Example 1 Kinetic analysis was performed on the C domain mutants in Table 1 by the following method. The experimental procedure was as follows: 1) IgG was cross-linked to a Series S CM5 chip. a. IgG was diluted to 5 μg / ml, 10 μg / ml, 15 μg / ml, and 20 μg / ml with 10 mM acetic acid-NaOH (pH 5.0). b. Prepare working buffer (10 mM acetic acid-NaOH, pH 5.0), stripping solution 1 (0.5% SDS), stripping solution 2 (50 mM glycine-NaOH, pH 9.5), blocking buffer (1 M ethanolamine pH 8.5), and activating agent (0.4 M EDC, 0.1 M NHS). c. Immobilization was performed on Biacore-4000. d. The cross-linking results are shown in the table below. TIFF2024543701000008.tif57156

[0213] 2)Dynamic analysis a. Protein samples (Protein A) were diluted with 1XPBS (pH 7.6) to 0 μg / ml, 1.615 μg / ml, 2.4375 μg / ml, 3.25 μg / ml, 4.875 μg / ml, 6.5 μg / ml, 9.75 μg / ml, 13 μg / ml, 19.5 μg / ml, and 26 μg / ml. b. Gel buffer: 1X PBS (pH 7.6) and regeneration solution (50 mM citric acid-NaOH pH 3.0) were prepared. c. Kinetics and affinity were performed on a Biacore-4000. TIFF2024543701000009.tif12156

[0214] The test results are as follows: [Table 1]

[0215] The results show that for all mutation sites, the KD values ​​were almost the same as for the natural C domain, and the dissociation constants did not change significantly, indicating that the mutants obtained by mutation in the C domain of the present invention have no effect on the binding ability to IgG.

[0216] Example 2 The IgG binding ability and alkaline stability of the C domain mutant affinity chromatography media in Table 2 were evaluated by the following methods. The experimental procedure was as follows: 1) 4.4 mL of C domain mutant affinity chromatography media was taken and loaded onto a chromatography column with 20% ethanol at a flow rate of 5 ml / min. Buffers: Buffer A (PBS, pH 7.6), Buffer B (0.1 M Sodium Citrate, pH 3.0), Buffer C (1 M NaOH). Sample: A 1 mg / ml purified IgG sample was prepared (the purified product was diluted with buffer A).

[0217] 2) Dynamic binding capacity measured at 10% breakthrough: Equipment: AKTA Pure. Measurement process: a. Buffer A balanced chromatography column, flow rate: 1.8 ml / min. b. If the IGg sample does not flow through the column, detect the UV absorption peak and measure λ max This results in 10% λ max was calculated. c. Sample load: Flow rate: 1.8 ml / min. The UV absorption peak of the basal outflow was recorded. d. The two were summed to obtain the UV absorption peak corresponding to the dynamic binding capacity measured at 10% breakthrough. e. Sample loading was continued until the UV absorption peak reached a volume corresponding to the UV absorption peak in step d, i.e., the dynamic binding capacity measured at 10% breakthrough.

[0218] 3) Resistance to alkaline cycles: The room temperature was controlled at 23±0.5° C., and the sample loading amount in the program was updated according to the decrease in binding capacity, while the other programs remained unchanged. Measurement process: a. PBS equilibration: flow rate: 1.8ml / min, volume: 1cv. b. Sample load: Flow rate: 1.8 ml / min, 200 ml (subsequent program updates sample load volume according to decreasing binding capacity). c. PBS wash: flow rate: 1.8ml / min, volume: 5cv. d. 0.1M Sodium Citrate Elution: Flow rate: 1.8ml / min, Volume: 3cv. e. Treated with 1M NaOH for 2 hours. First, 1 cv was run at a flow rate of 1.8 ml / min to fill the chromatography column with 1M NaOH, and then the flow rate was changed to 0.5 ml / min, volume: 60 ml, and time: 2 hours. f. PBS equilibration: flow rate: 1.8 ml / min, volume: 10 cv.

[0219] 4) The above alkali treatment process was carried out 13 times, and the corresponding binding capacities were recorded and graphed. The results are shown in Table 2 and Figure 2. Table 2 shows the DBC (calculated as dynamic binding loading, mg / ml) of IgG at 10% penetration (Qb10%) of each sample. [Table 2]

[0220] The results showed that the mutation sites selected by the present invention improved the alkaline stability of the native C domain, among which (Q9F)4 had 35.18% of the IgG dynamic binding capacity after 24 hours of alkaline treatment, while (E15I)4 had 41.86% of the IgG dynamic binding capacity after 24 hours of alkaline treatment.

[0221] Example 3 Example 2 was carried out using affinity chromatography media prepared with the C domain mutants in Table 3, and the results are shown in Table 3 and Figure 3. Table 3 shows the DBC (calculated as dynamic binding loading, mg / ml) of IgG at 10% penetration (Qb10%) for each sample. [Table 3]

[0222] The results showed that the alkaline resistance of the mutants of the present invention was significantly improved compared to the native C domain.

Claims

1. 1. An isolated polypeptide, the polypeptide comprising: (1) a polypeptide comprising the amino acid sequence shown in SEQ ID NO:109; (2) A polypeptide having at least 85% sequence identity with the polypeptide of (1) and having substitution mutations at positions 3, 6, 9 and 15 of SEQ ID NO:

109.

2. 2. The polypeptide of claim 1, wherein in SEQ ID NO:109, the 3rd, 6th, 9th and 15th substitution mutations are respectively selected from the following: the substitution mutation at position 3 is an asparaginate to leucine, valine, or tyrosine; the substitution mutation at position 6 is an asparaginate to serine, leucine, or glutamic acid substitution; the substitution mutation at position 9 is a substitution of glutamine to isoleucine, methionine, or phenylalanine; A polypeptide, wherein the substitution mutation at position 15 is a substitution of glutamic acid with threonine, tryptophan, leucine, valine, isoleucine, phenylalanine, serine, tyrosine, or aspartic acid.

3. 3. The polypeptide of claim 2, wherein in SEQ ID NO:109, the 3rd, 6th, 9th and 15th substitution mutations are respectively selected from the following: the substitution mutation at position 3 is an asparaginate to leucine or valine; the substitution mutation at position 6 is an asparaginate to leucine or glutamic acid substitution; the substitution mutation at position 9 is a substitution of glutamine to isoleucine or phenylalanine; A polypeptide, wherein the substitution mutation at position 15 is a substitution of glutamic acid with tryptophan, leucine, valine, isoleucine, or phenylalanine.

4. A polypeptide according to any one of claims 1 to 3, the polypeptide has the substitution mutation at position 3 of SEQ ID NO:109, and optionally at one or more positions selected from positions 6, 9, and 15; or the polypeptide has the substitution mutation at position 6 of SEQ ID NO:109, and optionally at one or more positions selected from positions 3, 9, and 15; or the polypeptide has the substitution mutation at position 9 of SEQ ID NO:109, and optionally has the substitution mutation at one or more positions selected from positions 3, 6 and 15; or the polypeptide has the substitution mutation at position 15 of SEQ ID NO:109, and optionally at one or more positions selected from positions 3, 6 and 9; or the polypeptide has the substitution mutations at positions 9 and 15 of SEQ ID NO:109, and optionally at any one or all two positions selected from positions 3 and 6; or the polypeptide has the substitution mutations at positions 3, 9 and 15 of SEQ ID NO:109, and optionally the substitution mutation at position 6; or The polypeptide has substitution mutations at positions 3, 6, 9 and 15 of SEQ ID NO:109, wherein the substitution mutation at position 3 is N3L or N3V, the substitution mutation at position 6 is N6L or N6E, the substitution mutation at position 9 is Q9I or Q9F, and the substitution mutation at position 15 is E15W, E15V, E15I or E15L.

5. 2. The polypeptide according to claim 1, characterized in that the amino acid sequence of the polypeptide is set forth in any one of SEQ ID NOs:2-73.

6. 1. An isolated polypeptide, characterized in that it is composed of the following (i), (ii) and (iii): (i) a polypeptide according to any one of claims 1 to 5, (ii) one or more coupling elements at the C-terminus or N-terminus of the amino acid sequence of the polypeptide according to (i), and optionally (iii) residues derived from a truncated signaling sequence.

7. 7. The polypeptide of claim 6, wherein the coupling element is selected from a cysteine ​​residue, a plurality of lysine residues and a plurality of histidine residues, and the residue of the truncated signaling sequence is AQ.

8. A fusion protein comprising an amino acid sequence formed by fusing 2 to 8 polypeptides according to any one of claims 1 to 5, wherein the 2 to 8 polypeptides are different from each other, partially identical or completely identical, and wherein a linker sequence is optionally present between the polypeptides.

9. 9. A fusion protein according to claim 8, wherein each of the polypeptides comprised in the fusion protein comprises at least an E15T, E15W, E15L, E15V, E15I, E15F, E15S, E15Y or E15T mutation, and preferably each of the polypeptides further comprises a substitution mutation at one or more of the third, sixth and ninth positions, preferably the substitution mutation at the third position is N3L or N3V, preferably the substitution mutation at the sixth position is N6L or N6E, and preferably the substitution mutation at the ninth position is Q9I or Q9F.

10. The fusion protein of claim 8, wherein the polypeptide is selected from SEQ ID NOs: 2, 3, 6, 7, 8, 9, 11-19, 21-25, 58-62 and 65-69.

11. A fusion protein according to any one of claims 8 to 10, characterized in that the C-terminus or N-terminus of the fusion protein further comprises one or more coupling elements and / or residues derived from a truncated signalling sequence, preferably the coupling elements being selected from a cysteine ​​residue, a plurality of lysine residues and a plurality of histidine residues.

12. The fusion protein according to claim 8, characterized in that the amino acid sequence of the fusion protein is set forth in any one of SEQ ID NOs:75-108.

13. A recombinant protein A, wherein the C domain of the recombinant protein A is a polypeptide described in any one of claims 1 to 5.

14. An isolated nucleic acid molecule, the polynucleotide sequence of which is (1) a polynucleotide sequence encoding a polypeptide according to any one of claims 1 to 7, a fusion protein according to any one of claims 8 to 12, or a recombinant protein A according to claim 13; (2) A nucleic acid molecule selected from the complementary sequence of the polynucleotide sequence of (1).

15. A nucleic acid construct, comprising a nucleic acid molecule according to claim 14, preferably wherein the nucleic acid construct is an expression cassette, more preferably wherein the nucleic acid construct is an expression vector or a cloning vector.

16. An expression system, comprising the nucleic acid construct of claim 15, preferably said expression system being a host cell.

17. 14. An isolation medium, characterized in that it comprises a polypeptide according to any one of claims 1-7, a fusion protein according to any one of claims 8-12 and / or a recombinant protein A according to claim 13 coupled to a solid support.

18. 18. The isolation medium according to claim 17, characterized in that the polypeptide, fusion protein or recombinant Protein A is coupled to the solid support by a thioether bond.

19. 19. The isolation medium of claim 18, wherein the solid support is a polyhydroxy-containing polymer, preferably a polysaccharide, more preferably a polymer selected from dextran, starch, cellulose, pullulan, agar, and agarose; a synthesized polymer, preferably selected from polyvinyl alcohol, polystyrene, polystyrene divinylbenzene, polyhydroxyalkyl acrylate, polyhydroxyalkyl methacrylate, polyacrylamide, and polymethacrylamide; An isolation medium, characterized in that it is chosen from supports of inorganic nature, preferably selected from silica, zirconia.

20. A chromatography column, characterized in that the chromatography column comprises an isolation medium according to any one of claims 17 to 19.

21. 21. A method for isolating an Fc-containing protein, the method comprising the step of contacting a sample containing an immunoglobulin with a polypeptide according to any one of claims 1-7, a fusion protein according to any one of claims 8-12, recombinant protein A according to claim 13, an isolation medium according to any one of claims 17-19 or a chromatography column according to claim 20, characterized in that the Fc-containing protein is an immunoglobulin.

22. 22. The method of claim 21, comprising: (1) contacting a sample containing an Fc-containing protein with the isolation medium; (2) washing the isolation medium; and (3) eluting the Fc-containing protein from the isolation medium; and (4) washing the isolation medium; Preferably, the method is characterized by washing the isolation medium with a 0.1-2.0M or 0.5-1.0M NaOH or KOH solution.

23. The use of a polypeptide according to any one of claims 1 to 7, a fusion protein according to any one of claims 8 to 12 or a recombinant protein A according to claim 13 in the isolation of an Fc-containing protein or in the manufacture of an isolation medium or a chromatography column for isolating an Fc-containing protein.

Citation Information

Patent Citations

  • Mutant immunoglobulin binding protein

    JP2005538693A

  • Mutant immunoglobulin-binding polypeptide

    JP2016523959A

  • Mutant immunoglobulin binding polypeptide

    JP2016525100A

  • Mutant immunoglobulin binding polypeptide

    JP2017533924A